French Biotech TargEDys® Announces Positive Results of Its Clinical Trial on the Weight Loss

▴ TargEDys
TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multi-centric clinical study carried out on 229 subjects and evaluating the efficacy of Hafnia alvei HA4597™ in the weight loss by regulation of the appetite.

TargEDys® in partnership with the University of Rouen Normandy, the University Hospital of Rouen and INSERM discovered that enterobacteria such as Hafnia alvei HA4597™ can produce a protein (ClpB) which is a mimetic of the satiety hormone α- MSH hence it is able to influence the mechanisms of appetite control at the peripheral and central level. Preclinical studies on Hafnia alvei HA4597™ have demonstrated anti-obesity effects such as weight loss, fat mass reduction as well as a reduced food intake and positive effects on blood sugar and insulin resistance.

TargEDys® has just confirmed clinically these pre-clinical data. The study was carried on overweight subjects characterized by a body mass index between 25 and 30 kg/m[2]. The two arms underwent a hypocaloric diet associated either with the Hafnia alvei HA4597™ probiotic or with a placebo. The primary endpoint related to weight loss has been achieved: there is a statistically significant difference in favor of the probiotic in the proportion of subjects who lost at least 3% of their body weight at 12 weeks. Amongst other secondary endpoints, the proposed mechanism of action is confirmed by a statistically significant increase in the feeling of fullness. Furthermore, the probiotic effect is also higher than the placebo in the reduction of hip circumference. Only the Hafnia alvei HA4597™ had an effect on cholesterol levels and induced a higher decrease in glycemia than the one observed with the placebo. Finally, Hafnia alvei HA4597™ has shown to be superior to the placebo through the overall evaluation of the benefits perceived by both the investigating physicians and the subjects.

"These results show a significant efficacy after already 2 months and which is reinforced at 3 months. The mechanism of action that had been described during the pre-clinical studies is confirmed," comments Pierre Déchelotte, co-founder and Clinical Advisor.

According to Gregory Lambert, CEO and vice-president of Research and Development in TargEDys®, "It is the first product of a new generation of probiotics, single strain, endowed with a scientifically established mechanism of action in the microbiome-gut-brain axis and with a proven short-term clinical efficacy."

"The success of this clinical trial is a turning point for TargEDys®. The clinical confirmation of all pre-clinical findings will boost the international commercial deployment of our network of partners for the commercialization of our unique nutritional solution, already sold in France under the name EnteroSatys™," said Jean-Frederic Laville, newly appointed Chief Business Officer.

Tags : #Weightloss #French #Biotech #Appetitecontrolmechanism #Medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025
India’s Newborns Are Dying from Sepsis And No One Is Talking About ItFebruary 27, 2025
Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks SoFebruary 26, 2025
The Inequality of Survival: Why Some Women Die While Others LiveFebruary 26, 2025
The Corporate Invasion of Indian Hospitals: What It Means for YouFebruary 26, 2025
5 Simple Daily Habits to Keep Your Joints Healthy and Pain-FreeFebruary 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in IndiaFebruary 25, 2025
With only 70 months left to end AIDS why is the urgency missing?February 25, 2025
Drenched in Oil: Is India Cooking Its Way to an Obesity Epidemic?February 25, 2025
Transforming Education: How Online Learning Platforms are Reshaping Study Material for Board and Competitive ExamsFebruary 24, 2025
February 24, 2025
The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West AfricaFebruary 24, 2025
The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing SystemFebruary 24, 2025
From Science Fiction to Reality: AI Now Detects Blindness Before It StartsFebruary 24, 2025